N-benzyl-2-chloro-9-cyclopentyl-9H-purin-6-amine | 310400-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-benzyl-2-chloro-9-cyclopentyl-9H-purin-6-amine
• 英文别名: 2-Chloro-6-[benzylamino]-9-cyclopentylpurine；N-benzyl-2-chloro-9-cyclopentylpurin-6-amine
• CAS: 310400-99-8
• 化学式: C₁₇H₁₈ClN₅
• 分子量: 327.816
• InChiKey: APURIMWVMQIOPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-benzyl-2-chloro-9-cyclopentyl-9H-purin-6-amine 在 potassium [18F]fluoride 、 potassium carbonate 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 水 、 乙腈 为溶剂， 反应 0.17h， 生成 N-benzyl-9-cyclopentyl-2-(fluoro-18F)-9H-purin-6-amine
  参考文献：
  名称：

  [EN] IMAGING AGENTS FOR NEURAL FLUX
  [FR] AGENTS D'IMAGERIE POUR FLUX NEURONAL

  摘要：

  本文提供了用于非侵入性成像技术的放射性标记化合物。本文提供的一种示例性放射性标记化合物可用作正电子发射断层扫描的放射示踪剂。本申请还提供了用于治疗中枢神经系统疾病或外周神经系统疾病的未标记化合物。还提供了制备放射性标记化合物、制备未标记化合物以及使用标记化或未标记化化合物的诊断方法。

  公开号：

  WO2016011394A1
• 作为产物：
  描述：

  2,6-二氯嘌呤 在 偶氮二甲酸二异丙酯 、 三苯基氧化膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 19.0h， 生成 N-benzyl-2-chloro-9-cyclopentyl-9H-purin-6-amine
  参考文献：
  名称：

  [EN] A CYCLIN-DEPENDENT KINASE INHIBITOR
  [FR] INHIBITEUR DE KINASE DÉPENDANTE DE LA CYCLINE

  摘要：

  提供了一系列具有很强的抑制周期素依赖性激酶（CDK）活性的化合物或其药用可接受的盐。同时也提供了相应的组合物。

  公开号：

  WO2022206795A1

文献信息

• Derivatives of purine, their preparation process and pharmaceutical compositions containing them
  申请人：Haesslein Jean-Luc

  公开号：US20050187228A1

  公开（公告）日：2005-08-25

  A compound of the formula wherein R is defined as in the specification, which compounds have an inhibitory effect vis-à-vis cycline-dependent kinase proteins (cdk) and are endowed with antimitotic properties.

  其中R在规范中定义，该化合物具有对细胞周期依赖性激酶蛋白（cdk）具有抑制作用并具有抗有丝分裂特性。
• 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06413974B1

  公开（公告）日：2002-07-02

  The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or H2N—R3— wherein R2 is selected from the group consisting of C1-C8 alkyl and  wherein Z is selected from the group consisting of phenyl, heterocycle and cycloalkyl, each R4 is independently hydrogen or C1-C4 alkyl, and n is an integer 1-8; wherein each C1-C8 alkyl and Z is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of Ha1, OH, and C1-C4 alkyl; R3 is C1-C8 alkylene; and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof. In addition, the present invention provides a method of inhibiting cell cycle progression. More specifically, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms. In addition, the present invention provides a composition comprising an assayable amount of a compound of Formula (I) in admixture or otherwise in association with an inert carrier. The present invention also provides a pharmaceutical composition comprising an effective inhibitory amount of a compound of Formula (I) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

  本发明提供了公式（I）中的新化合物，其中R选自由R2、R2NH—或H2N—R3—的组，其中R2选自C1-C8烷基的组，Z选自苯基、杂环和环烷基的组，每个R4独立地为氢或C1-C4烷基，n为1-8的整数；其中每个C1-C8烷基和Z可选地与1到3个取代基取代，这些取代基可以是相同的或不同的，选自Ha1、OH和C1-C4烷基的组；R3为C1-C8烷基；R1选自环戊基和异丙基的组，以及其药学上可接受的盐、光学异构体和水合物。此外，本发明提供了一种抑制细胞周期进展的方法。更具体地说，本发明提供了一种抑制cyclin依赖性激酶，特别是cdk-2的方法。本发明还提供了一种防止神经细胞凋亡和抑制肿瘤发展的方法。此外，本发明提供了一种包含公式（I）化合物的测定量的组合物，与惰性载体混合或以其他方式结合。本发明还提供了一种包含有效抑制量的公式（I）化合物的药物组合物，与一个或多个药学上可接受的载体或赋形剂混合或以其他方式结合。
• Purine derivatives, preparation method and pharmaceutical compositions containing same
  申请人：Hoechst Marion Roussel

  公开号：US07122669B1

  公开（公告）日：2006-10-17

  Derivatives of purine having anti-proliferative properties and in particular, derivatives of purine endowed with an inhibitory effect vis-a-vis cycline-dependent kinase proteins i.e. abbreviated to “cdk”.

  嘌呤的衍生物具有抗增殖特性，特别是具有针对细胞周期蛋白依赖性激酶蛋白（简称“cdk”）的抑制作用的嘌呤衍生物。
• Imaging agents for neural flux
  申请人：The General Hospital Corporation

  公开号：US10519160B2

  公开（公告）日：2019-12-31

  Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.

  本文提供的放射性标记化合物可用于非侵入性成像技术。本文提供的一种示例性放射性标记化合物可用作正电子发射断层扫描的放射性示踪剂。本申请还提供了用于治疗中枢神经系统疾病或周围神经系统疾病的未标记化合物。还提供了制备放射性标记化合物、制备未标记化合物的方法，以及使用标记或未标记化合物的诊断方法。
• Development of Potent Purine-Derived Nitrile Inhibitors of the Trypanosomal Protease TbcatB
  作者：Jeremy P. Mallari、Anang A. Shelat、Terri Obrien、Conor R. Caffrey、Aaron Kosinski、Michele Connelly、Michael Harbut、Doron Greenbaum、James H. McKerrow、R. Kiplin Guy

  DOI：10.1021/jm070760l

  日期：2008.2.1

  Human African trypanosomiasis (HAT), a major health concern in sub-Saharan Africa, is caused by the protozoan parasite Trypanosoma brucei. Recent studies have shown that a cathepsin B like protease, TbcatB, is essential to the survival of T brucei in vitro (Mackey, Z. B.; O'Brien, T. C.; Greenbaum, D. C.; Blank, R. B.; McKerrow, J. H. J. Biol. Chem. 2004, 279, 48426-48433). Herein, we describe the first inhibitors of TbcatB, a series of purine nitriles. The compounds are potent trypanocides, killing the parasite with a high degree of selectivity over a panel of three human cell lines. In addition, a predictive model of trypanocidal activity was developed on the basis of potency against TbcatB and various calculated physical property descriptors.